Cidara Therapeutics, Inc. - Common Stock (NQ:CDTX)

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Topics Regulatory Compliance

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Cidara Therapeutics Stock Rockets Over 700% This Year — Then Wall Street Turns Neutral On Merck Takeover ↗

November 17, 2025

Via Stocktwits

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Via MarketMinute

Topics ETFs Economy Intellectual Property

Halper Sadeh LLC Encourages EB, KPLT, WBD, CDTX Shareholders to Contact the Firm to Discuss Their Rights

December 18, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights

Halper Sadeh LLC Encourages CADE, MRSN, CDTX Shareholders to Contact the Firm to Discuss Their Rights

December 10, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mersana Therapeutics, Inc. (Nasdaq - MRSN), Cidara Therapeutics, Inc. (Nasdaq - CDTX), Cadence Bank (NYSE – CADE)

December 10, 2025

From Brodsky & Smith LLC

Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights

December 08, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

After a long hiatus, why are the bulls so willing to buy in now?

Merck's Stock is Suddenly Soaring, but Is the Struggling Healthcare Giant a Buy? ↗

December 07, 2025

The rebound is well underway.

Topics Intellectual Property

Is This Pharmaceutical Giant a Buy After a Major Acquisition? ↗

December 05, 2025

There are plenty of potential winners outside the world of AI.

Topics Death

3 Non-AI Stocks to Buy: MRK, UPS, CVX ↗

November 30, 2025

The struggling pharmaceutical giant is showing signs of life.

Topics Artificial Intelligence

Should You Buy This Blue Chip Pharmaceutical Stock That Just Popped 3.8%? ↗

November 29, 2025

Halper Sadeh LLC Encourages AXTA, SEMR, CDTX Shareholders to Contact the Firm to Discuss Their Rights

November 27, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights

Halper Sadeh LLC Encourages THS, CDTX, SPNS Shareholders to Contact the Firm to Discuss Their Rights

November 22, 2025

Shareholders should contact the firm immediately as there may be limited time to enforce your rights

Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter

Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗

November 20, 2025

Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way

Topics Artificial Intelligence Regulatory Compliance

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗

November 20, 2025

Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs? ↗

Topics Regulatory Compliance

November 20, 2025

The pharmaceutical giant's post-Keytruda plans continue to take shape.

Shares in the biotech company have surged on news of a big pharma takeover.

Topics Intellectual Property

Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. ↗

November 20, 2025

Bain Capital sold its entire stake in Nuvalent stock during the third quarter.

Biotech Stock Gets Booted in Latest Fund Update ↗

November 19, 2025

Bain Capital completely exited its position in Disc Medicine stock during the third quarter

Topics Regulatory Compliance

Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗

November 19, 2025

Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.

Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything ↗

November 18, 2025

Via MarketBeat

Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗

November 18, 2025

This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗

Topics Regulatory Compliance

November 17, 2025

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.

Cidara Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cidara Therapeutics, Inc. - CDTX

Top 2 Health Care Stocks That May Fall Off A Cliff This Month ↗

November 17, 2025

Via Benzinga

November 16, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗

November 14, 2025

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Via Chartmill

Which stocks are moving on Friday? ↗

November 14, 2025

Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 14, 2025

Via Benzinga

Gold Tumbles Over 2%; Cidara Therapeutics Shares Spike Higher ↗

November 14, 2025

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cidara Therapeutics, Inc. (Nasdaq - CDTX), Mersana Therapeutics, Inc. (Nasdaq - MRSN), TreeHouse Foods Inc. (NYSE - THS), Gulf Island Inc. (Nasdaq - GIFI)

November 14, 2025

From Brodsky & Smith LLC